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It is known that abnormal sympathoexcitation is involved in the
athogenesis of chronic heart failure, and the sympathetic nerve
ctivity is mainly and quickly regulated by baroreﬂex [1]. Inter-
stingly, the arterial baroreﬂex is impaired both in heart failure
ith reduced left ventricular ejection fraction (HFrEF) and with
reserved left ventricular ejection fraction (HFpEF) [1–5]. The arte-
ial baroreﬂex system is an important and powerful regulator of the
tressed blood volume and systemic blood pressure [6–8]. The ben-
ﬁts of baroreﬂex activation therapy (BAT) in the treatment of heart
ailure have been already demonstrated in animals and humans
3,5,9–11].
In this issue of the Journal of Cardiology Cases, Brambilla et al.
12] report that BAT substantially improved the clinical course of
 post-myocardial infarction HFrEF patient with recent, repeated,
nd lengthy hospitalizations for worsening heart failure. They
mplanted the BarostimTM neo system (CVRx, Inc., Minneapolis,
N, USA) to a severe [New York Heart Association (NYHA) class III]
9-year-old male with left ventricular systolic dysfunction, signs of
ight ventricular failure, stage 3 chronic kidney disease, and insulin-
ependent diabetes. In the acute phase, cardiac output increased
ith pulmonary artery systolic pressure and wedge pressure drop-
ing. Moreover, in the chronic phase, muscle sympathetic nerve
ctivity was chronically reduced through 6 months, and the 6-min
all walk distance, NYHA class, and serum brain natriuretic pep-
ide improved. Does this case shed additional light on the clinical
mplications for severe heart failure? It likely does. In particular, the
resent case highlights the potential of systemic neuromodulation
y BAT as a powerful new approach for advanced HFrEF.
We  should discuss whether BAT could have beneﬁts for only
FrEF. How about HFpEF? A recent study indicated that barore-
ex activation could be a novel therapeutic strategy for patients
ith diastolic heart failure [3,11]. Recently, we have reported the
ole of baroreﬂex failure in HFpEF [13]. Left ventricular diastolic
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878-5409 © 2014 Japanese College of Cardiology. Published by Elsevier Ltd. Open accessdysfunction is induced by arterial baroreﬂex failure [2]. We  exam-
ined whether baroreﬂex failure (FAIL) mimicked by constant
carotid sinus pressure (CSP) causes a striking increase in left atrial
pressure (LAP) and systemic arterial pressure (AP) by volume load-
ing in rats with normal left ventricular function. We  mimicked the
normal baroreﬂex by matching CSP to instantaneous AP and FAIL
by maintaining CSP at a constant value regardless of AP. We  infused
dextran stepwise [infused volume (Vi)] until LAP reached 15 mmHg
and obtained the LAP-Vi relationship. We estimated the critical
Vi as the Vi at which LAP reached 20 mmHg. In FAIL, critical Vi
decreased markedly, while AP at the critical Vi increased. Moreover,
we demonstrated that an artiﬁcial baroreﬂex system we  recently
developed could fully restore the physiological volume intolerance
in the absence of native arterial baroreﬂex. Our results strongly
indicated that baroreﬂex failure induces striking volume intoler-
ance in the absence of left ventricular dysfunction and may  play an
important role in the pathogenesis of acute heart failure, especially
in states of HFpEF. We  also consider that the bionic arterial barore-
ﬂex system would be an attractive therapeutic tool in preventing
the volume intolerance in acute decompensated heart failure.
As  the authors readily acknowledge, the present paper is just
one case report. Randomized, controlled trials are underway to
validate the safety and efﬁcacy of BAT in a broader HFrEF popula-
tion. Nevertheless, the present case may  have clinical implications
regarding the importance of BAT in the treatment of HFrEF. In addi-
tion, we should consider that BAT also has beneﬁt on HFpEF. Acute
heart failure demonstrates an elevated ﬁlling pressure in response
to increased circulatory volume in both HFrEF and HFpEF [14]. In
this regard, BAT might have a potential to be a therapy for “heart
failure notwithstanding left ventricular ejection fraction.”
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